The number of US residents with OA in 2016 is estimated at over 30 million
The burden to society of OA in developed counties is in excess of 2% annual GDP
Increased risk of cardiovascular disease, diabetes, hypertension and early death
Activity limitations 80% – increased risk of early death. Current therapies have small effect, costly and associated with life threatening adverse events.
Osteoarthritis is a chronic, painful, degenerative, progressive arthropathy that is one of the leading causes of pain and disability worldwide. It affects ~10% global population >60-years old ( Pereira 2011).
The dose and duration of commonly prescribed OA drugs is restricted due to their cardiovascular toxicities and poor gastrointestinal tolerance. These restrictions drive the need for an effective, well tolerated drug for long term use and significant unmet medical need continues to exist for pain relief associated with OA.
APPA is the only oral NCE with an MoA that targets multiple signaling pathways in bone, cartilage and inflammation that are involved in OA, with potential for slowing the progression of the disease
For more information on OA, please visit Versus Arthritis.